Wait Suzanne, Alvarez-Rosete Arturo, Osama Tasnime, Bancroft Dani, Cornelissen Robin, Marušić Ante, Garrido Pilar, Adamek Mariusz, van Meerbeeck Jan, Snoeckx Annemiek, Leleu Olivier, Hult Ebba Hallersjö, Couraud Sébastien, Baldwin David R
The Health Policy Partnership, London, United Kingdom.
Department of Pulmonology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
JTO Clin Res Rep. 2022 Apr 22;3(5):100329. doi: 10.1016/j.jtocrr.2022.100329. eCollection 2022 May.
Lung cancer is the leading cause of cancer death in Europe. Screening by means of low-dose computed tomography (LDCT) can shift detection to an earlier stage and reduce lung cancer mortality in high-risk individuals. However, to date, Poland, Croatia, Italy, and Romania are the only European countries to commit to large-scale implementation of targeted LDCT screening. Using a health systems approach, this article evaluates key factors needed to enable the successful implementation of screening programs across Europe. Recent literature on LDCT screening was reviewed for 10 countries (Belgium, Croatia, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, and United Kingdom) and complemented by 17 semistructured interviews with local experts. Research findings were mapped against a health systems framework adapted for lung cancer screening. The European policy landscape is highly variable, but potential barriers to implementation are similar across countries and consistent with those reported for other cancer screening programs. While consistent quality and safety of screening must be ensured across all screening centers, system factors are also important. These include appropriate data infrastructure, targeted recruitment methods that ensure equity in participation, sufficient capacity and workforce training, full integration of screening with multidisciplinary care pathways, and smoking cessation programs. Stigma and underlying perceptions of lung cancer as a self-inflicted condition are also important considerations. Building on decades of implementation research, governments now have a unique opportunity to establish effective, efficient, and equitable lung cancer screening programs adapted to their health systems, curbing the impact of lung cancer on their populations.
肺癌是欧洲癌症死亡的主要原因。通过低剂量计算机断层扫描(LDCT)进行筛查可以将检测提前到更早阶段,并降低高危人群的肺癌死亡率。然而,迄今为止,波兰、克罗地亚、意大利和罗马尼亚是欧洲仅有的承诺大规模实施针对性LDCT筛查的国家。本文采用卫生系统方法,评估了在欧洲成功实施筛查项目所需的关键因素。对10个国家(比利时、克罗地亚、法国、德国、意大利、荷兰、波兰、西班牙、瑞典和英国)关于LDCT筛查的最新文献进行了综述,并辅以对当地专家的17次半结构化访谈。研究结果对照了一个适用于肺癌筛查的卫生系统框架进行梳理。欧洲的政策环境差异很大,但实施的潜在障碍在各国相似,且与其他癌症筛查项目报告的障碍一致。虽然必须确保所有筛查中心的筛查质量和安全性一致,但系统因素也很重要。这些因素包括适当的数据基础设施、确保参与公平性的针对性招募方法、足够的能力和劳动力培训、筛查与多学科护理路径的充分整合以及戒烟项目。耻辱感以及将肺癌视为自身造成的疾病的潜在观念也是重要的考虑因素。基于数十年的实施研究,各国政府现在有一个独特的机会来建立适应其卫生系统的有效、高效和公平的肺癌筛查项目,遏制肺癌对其民众的影响。